This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Buy These 4 Efficient Stocks for Impressive Returns
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Why Should You Add Haemonetics (HAE) to Your Portfolio Now?
by Zacks Equity Research
Market seems to be upbeat about Haemonetics' (HAE) newly-launched platform, NexSys Plasma Collection System (PCS).
Cerus (CERS) Looks Good: Stock Adds 9.5% in Session
by Zacks Equity Research
Shares of Cerus (CERS) rose 9.5% on Friday
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
by Zacks Equity Research
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
5 Top-Ranked Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level will provide impressive returns irrespective of market conditions
Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) upbeat on integration of NexSys PCS device. A raised EPS guidance buoys optimism.
Medical Device Industry Outlook - February 2018
by Zacks Equity Research
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.
Here's Why You Must Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.
Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips
International Business Aids NuVasive, Pricing Woe Remains
by Zacks Equity Research
NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.
5 Top Efficient Stocks to Add to Your Portfolio
by Tirthankar Chakraborty
Companies with favorable efficiency levels are likely to be on investors' radar irrespective of market conditions as price performance is believed to be positively correlated with efficiency
BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.
NuVasive's SpineTRACK Registry Gains New CMS Designation
by Zacks Equity Research
NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.
Luminex (LMNX) Banks on Solid Product Line, Competition Rife
by Zacks Equity Research
Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.
Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis
by Zacks Equity Research
Abiomed (ABMD) gets second FDA PMA for its flagship Impella in a row, with a view to treating patients with High Risk PCI.
Haemonetics (HAE) Banks on Plasma Franchise, Competition Rife
by Zacks Equity Research
Haemonetics' (HAE) strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth.
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) gains from promising financial results in the third quarter of fiscal 2018.
Is Surprise Coming for Haemonetics (HAE) This Earnings Season?
by Zacks Equity Research
Is Surprise Coming for Haemonetics (HAE) This Earnings Season?
Haemonetics Banks on Hospital Business, Competition Rife
by Zacks Equity Research
For fiscal 2018, Haemonetics (HAE) expects the Hospital business to grow 7-10%.
Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.
Haemonetics (HAE) Grows on Strong Plasma, Competition Rife
by Zacks Equity Research
Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.
Haemonetics (HAE) in Focus: Stock Moves 10% Higher
by Zacks Equity Research
Haemonetics (HAE) saw its shares rise nearly 10% on the day after the company reported better-than-expected second quarter and first Half Fiscal 2018 results.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.